DexCom (NASDAQ: DXCM) has outperformed the market over the past 10 years by 2.92% on an annualized basis producing an average annual return of 16.14%. Currently, DexCom has a market capitalization of ...
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...
StockStory.org on MSN
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex shares plummet, what you need to know
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...
We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 ...
One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...
DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.
The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...
Looking into the current session, DexCom Inc. (NASDAQ:DXCM) shares are trading at $69.95, after a 0.09% increase. Moreover, over the past month, the stock spiked by 2.13%, but in the past year, fell ...
DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results